Regent Pacific (575 HK)

Analysis

Health Care • Hong Kong

Regent Pacific is an investment holding company focused on the healthcare and life sciences sectors. It engages in the research, development, manufacturing, marketing, and sale of pharmaceutical products for urological disorders, such as Fortacin™/Senstend™, and develops AI systems for biological aging clocks through Deep Longevity. The company was founded in 1991 and is headquartered in Central, Hong Kong.

Refresh

Focused

bullish•Regent Pacific

•08 Aug 2026 22:02

Primer: Regent Pacific (575 HK) - Aug 2026

Regent Pacific is transitioning to a commercial-stage biopharmaceutical company, with the recent approval of its premature ejaculation...

αSK Primers

99 Views

bearish•Television Broadcasts

•07 Apr 2017 15:01

TVB - Whitewash Musings

The despatch of Television Broadcasts Ltd (511 HK)'s Offer Document has been delayed thrice since TLG’s "bid" failed to materialise.The last two...

David Blennerhassett

957 Views

No more insights

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00